FOCUS on New Drug Approvals. On April 13th the FDA approved Travere Therapeutics’ Sparsentan (Filspari) as the first approved treatment for reduction of proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis (FSGS). FSGS is a rare kidney disease characterized by scarring. Sparsentan is a DARA (Dual Acting Receptor Antagonist) acting as an endothelin A and angiotensin II receptor antagonist. It was previously approved for reducing proteinuria in immunoglobulin A nephropathy.
FOCUS Biomolecules can supply Sparsentan for research applications. Contact us for more information.
